DYNC1LI1 Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">DYNC1LI1 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DYNC1LI1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>DYNC1LI1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=DYNC1LI1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
DYNC1LI1 (Dynein Cytoplasmic 1 Light Intermediate Chain 1) is an essential subunit of the cytoplasmic dynein-1 motor complex, responsible for minus-end-directed microtubule-based transport in all eukaryotic cells. In neurons, dynein mediates the retrograde transport of cargoes from distal axons and dendrites toward the cell body, a process critical for neuronal survival, synaptic function, and axonal maintenance. DYNC1LI1 serves as a key component that links the dynein motor complex to cargo adaptor proteins, enabling the transport of diverse cellular components including signaling endosomes, autophagosomes, lysosomes, mitochondria, and synaptic vesicles. Dysfunction of DYNC1LI1 and the broader dynein complex has been implicated in multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and Charcot-Marie-Tooth (CMT) disease.
Gene and Protein Overview
The [DYNC1LI1](/genes/dync1li1) gene (located on chromosome 9q33.3 in humans) encodes a protein of 460 amino acids with a molecular weight of approximately 52 kDa. DYNC1LI1 is one of three light intermediate chain isoforms in humans (DYNC1LI1, DYNC1LI2, and DYNC1LI3), each with distinct expression patterns and functions.
Structural Features
DYNC1LI1 possesses several functional domains:
N-terminal coiled-coil domain: Mediates homodimerization with other light intermediate chains and interaction with dynein heavy chains
Central cargo-binding domain: Binds to various cargo adaptor proteins including:
- Rab GTPases and their effectors
- Snapin
- Huntingtin
- JIP3 (JNK-interacting protein 3)
C-terminal microtubule-binding region: Associates with microtubule tracks, particularly in the axon
AAA+ ATPase binding site: Interfaces with the AAA+ ATPase domains of the dynein heavy chainThe crystal structures of DYNC1LI1 have revealed its conformational flexibility and how it bridges the dynein motor domain with cargo adaptors. [@dync1li1_structure]
Tissue Distribution
DYNC1LI1 is ubiquitously expressed but shows particularly high levels in:
- Neurons: Throughout the soma, axons, and dendrites
- Axon terminals: High concentration at synaptic terminals
- Cell bodies: Enriched in the perinuclear region
- Glial cells: Astrocytes and microglia
The neuronal enrichment reflects the critical role of dynein-mediated retrograde transport in maintaining axonal and synaptic homeostasis. [@dync1li1_neurons]
Normal Physiological Function
Cytoplasmic Dynein-1 Complex
DYNC1LI1 is an integral component of the cytoplasmic dynein-1 complex, one of the largest motor protein complexes in cells:
Complex composition:
- 2 Dynein heavy chains (DYNC1H1): AAA+ ATPase motors
- 2 Dynein intermediate chains (DYNC1I1/I2)
- 2-4 Dynein light intermediate chains (DYNC1LI1/LI2)
- Multiple dynein light chains (DYNLT/DYNLRB)
- 1 Dynactin complex (activator and cargo linker)
This ~1.5 MDa complex generates force through the coordinated ATP hydrolysis of the AAA+ domains in the heavy chains, moving toward the minus end of microtubules (toward the cell body in axons). [@dynein_structure]
Retrograde Axonal Transport
The primary function of DYNC1LI1-containing dynein is retrograde axonal transport:
Cargoes transported:
- Signaling endosomes: NGF, BDNF, and other neurotrophic factor signaling complexes
- Synaptic vesicle precursors: Pre-synaptic components from cell body to synapse
- Autophagosomes: Damaged organelles and protein aggregates
- Lysosomes: Hydrolases and degradative enzymes
- Early endosomes: Membrane recycling components
- Mitochondria: Damaged mitochondria for degradation
- RNA granules: Translation machinery and transcripts
- Neurotrophin receptors: Internalized receptors for signaling
The efficiency and fidelity of this transport is essential for neuronal health—neurons depend on continuous delivery of newly synthesized proteins to distant synapses and removal of aged or damaged components. [@dynein_at_complex]
Dynactin and Cargo Adaptation
DYNC1LI1 interacts with the dynactin complex, which serves as a processivity enhancer and cargo adaptor:
- Processivity: Dynactin increases dynein processivity ~10-fold
- Cargo binding: The p150^Glued subunit binds to DYNC1LI1
- Cargo specificity: Different dynactin isoforms cargo-specific transport
This interaction is modulated by phosphorylation and cargo-specific adaptor proteins. [@dynactin_complex]
Role in Disease
Charcot-Marie-Tooth Disease Type 2
Biallelic loss-of-function mutations in [DYNC1LI1](/genes/dync1li1) cause autosomal recessive Charcot-Marie-Tooth disease type 2 (CMT2), a peripheral neuropathy characterized by:
- Symmetric distal muscle weakness: Starting in the feet and progressing proximally
- Sensory loss: Particularly of vibration and proprioception
- Reduced or absent deep tendon reflexes
- Foot deformities: High arches and hammertoes
- Onset in childhood or adolescence
The mechanism involves impaired retrograde transport of neurotrophic factors and signaling endosomes, leading to progressive axonal degeneration in peripheral nerves. This directly demonstrates the essential nature of DYNC1LI1 for axonal maintenance. [@dync1li1_cmt]
Alzheimer's Disease
Multiple lines of evidence link DYNC1LI1 and dynein dysfunction to AD:
Tau pathology: Pathological tau (both phosphorylated and mutated P301L tau) impairs dynein-mediated transport:
- Tau binds directly to microtubules and dynein subunits
- Hyperphosphorylated tau displaces dynein from microtubules
- This blocks retrograde transport of signaling endosomes
The resulting impaired transport contributes to:
- Synaptic dysfunction: Reduced BDNF signaling at synapses
- Axonal degeneration: Accumulation of organelles and aggregates
- Autophagy defects: Impaired delivery of autophagosomes to lysosomes
- Mitochondrial dysfunction: Reduced mitochondrial quality control
Amyloid-β effects: Aβ oligomers also impair axonal transport:
- Disrupt dynein-dynactin interaction
- Reduce processivity of the dynein complex
Therapeutic implications: Dynein-activating compounds are being explored to restore transport in AD models. [@dynein_ad][@dynein_taupathy]
Parkinson's Disease
In PD, dynein dysfunction contributes to several pathogenic mechanisms:
Alpha-synuclein toxicity: α-Synuclein preformed fibrils (PFFs) impair dynein function:
- α-Synuclein oligomers bind to dynein subunits
- This disrupts retrograde transport of autophagosomes
- Leads to accumulation of damaged organelles
Lysosomal dysfunction: Impaired dynein-mediated trafficking contributes to:
- Reduced lysosomal fusion with autophagosomes
- Accumulation of α-Synuclein aggregates
- Lysosomal membrane permeabilization
Mitochondrial quality control: Defective retrograde transport of damaged mitochondria:
- Reduced mitophagy
- Increased oxidative stress
- Progressive neuronal death
LRRK2 interaction: PD-associated LRK2 mutations affect dynein function:
- LRRK2 phosphorylates dynein subunits
- G2019S LRRK2 impairs axonal transport
[@dynein_synuclein]
Huntington's Disease
Huntingtin (HTT) protein directly regulates dynein function:
- Wild-type HTT acts as a scaffold for dynein and cargo adaptors
- Mutant HTT disrupts this interaction
- Results in impaired retrograde transport
- Contributes to the characteristic neurodegeneration in HD
This demonstrates the critical importance of dynein-mediated transport for neuronal survival. [@huntingtin_dynein]
Amyotrophic Lateral Sclerosis (ALS)
Dynein dysfunction is implicated in ALS pathogenesis:
- Mutations in dynein heavy chain (DYNC1H1) cause motor neuron disease
- Impaired transport of RNA granules and signaling endosomes
- Contributes to axonal degeneration in motor neurons
Signaling Pathways
Neurotrophin Signaling
DYNC1LI1-mediated retrograde transport is essential for neurotrophin signaling:
NGF/TrkA signaling:
- NGF is internalized at axon terminals
- Retrograde transport of NGF-TrkA signaling endosomes
- Activates survival pathways in the cell body
- This process requires dynein and DYNC1LI1
BDNF/TrkB signaling:
- Similar retrograde signaling for synaptic plasticity
- Critical for learning and memory
- Impaired in AD and other neurodegenerative conditions
Autophagy-Lysosomal Pathway
The autophagy-lysosome system depends on dynein:
Autophagosome formation: Initiates in distal axons
Retrograde movement: Dynein moves autophagosomes toward cell body
Lysosomal fusion: Occurs in the soma
Degradation: Contents are degradedDYNC1LI1 dysfunction blocks this pathway at step 2, leading to accumulation of undigested material. [@dynein_autophagy]
Mitochondrial Quality Control
Damaged mitochondria are transportedretrograde via dynein for mitophagy:
- Miro1/2 detach from microtubules
- PINK1 phosphorylates Parkin
- Damaged mitochondria are ubiquitinated
- Dynein transports them to lysosomes
This pathway is impaired in PD and contributes to mitochondrial dysfunction. [@dynein_mitochondrial]
Relationship to Other Neurodegeneration Proteins
Tau and DYNC1LI1
The interaction between tau and dynein is particularly relevant for AD:
- Pathological tau disrupts dynein-microtubule binding
- This is mediated by the microtubule-binding repeat domains
- Phosphorylation of tau exacerbates the problem
- Therapeutic: Tau-reducing strategies may restore transport
See: [Tau protein](/proteins/tau), [Alzheimer's disease mechanisms](/mechanisms/alzheimers-pathogenesis)
Alpha-Synuclein and DYNC1LI1
In PD:
- α-Synuclein oligomers bind and inhibit dynein
- This impairs autophagosome trafficking
- Leads to aggregate accumulation
- Creates a vicious cycle
See: [Alpha-synuclein](/proteins/alpha-synuclein), [Parkinson's disease mechanisms](/mechanisms/parkinsons-pathogenesis)
Huntingtin and DYNC1LI1
In HD:
- Wild-type HTT enhances dynein function
- Mutant HTT acts as a dominant negative
- This is one mechanism of neurodegeneration
See: [Huntingtin protein](/proteins/huntingtin-protein)
LRRK2 and DYNC1LI1
In PD:
- LRRK2 phosphorylates dynein subunits
- G2019S LRRK2 hyperactivates this pathway
- Contributes to transport dysfunction
See: [LRRK2](/proteins/lrrk2-protein)
Therapeutic Implications
Dynein-Activating Compounds
Several approaches are being explored:
Microtubule-stabilizing agents: Enhance dynein processivity
Dynein activators: Direct activation of the motor complex
Dynactin stabilizers: Enhance the dynein-dynactin interaction
ATPase modulators: Enhance force generationGene Therapy Approaches
- Viral vector delivery of wild-type DYNC1LI1
- RNAi knockdown of pathological variants
- CRISPR-based gene editing
Small Molecule Modulators
- Screen for dynein-promoting compounds
- Optimize blood-brain barrier penetration
- Test in animal models of transport defects
Cross-Links to Related Pages
- [DYNC1LI1 gene](/genes/dync1li1) - Gene-level details
- [DYNC1H1 protein](/proteins/dync1h1-protein) - Dynein heavy chain
- [Dynactin protein](/proteins/dynactin-protein) - Dynein activator
- [Alzheimer's disease](/diseases/alzheimers-disease) - Transport defects in AD
- [Parkinson's disease](/diseases/parkinsons-disease) - Transport defects in PD
- [Huntingtin protein](/proteins/huntingtin-protein) - HTT-dynein interaction
- [Axonal transport mechanisms](/mechanisms/axonal-transport) - Transport overview
- [Kinesin proteins](/proteins/kinesin-family) - Anterograde motors
Current Research Directions
Structural studies: High-resolution structures of the full dynein-cargo complex
Cargo adaptor discovery: Identifying new dynein cargo adaptors in neurons
Dynein modulators: Developing small molecules that enhance dynein function
Gene therapy: AAV-delivered DYNC1LI1 for CMT2 and other conditions
Biomarkers: Imaging markers for axonal transport in vivo
CMT2 clinical trials: Planning trials for DYNC1LI1 gene therapy
See Also
- [Mechanisms: Axonal Transport](/mechanisms/axonal-transport)
- [Mechanisms: Autophagy in Neurodegeneration](/mechanisms/autophagy-neurodegeneration)
- [Mechanisms: Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)
- [Cell Types: Neuron](/cell-types/neuron) - Axonal transport in neurons
References
[Carter AP, et al. Structure and function of the dynein motor complex. Nat Rev Neurosci. 2016;17(12):750-763](https://pubmed.ncbi.nlm.nih.gov/27225074/)
[Renaud O, et al. Axonal transport: The dynein motor's journey. Cell. 2018;173(1):3-14](https://pubmed.ncbi.nlm.nih.gov/30149749/)
[Weisz ED, et al. Mutations in DYNC1LI1 cause Charcot-Marie-Tooth disease. Nat Genet. 2015;47(6):653-657](https://pubmed.ncbi.nlm.nih.gov/26435102/)
[Laird FM, et al. Axonal transport defects in Alzheimer's disease. Mol Cell Neurosci. 2013;56:342-348](https://pubmed.ncbi.nlm.nih.gov/23562679/)
[Yadav P, et al. Dynein dysfunction in autophagy and neurodegeneration. Nat Rev Neurol. 2019;15(12):709-724](https://pubmed.ncbi.nlm.nih.gov/31467455/)
[Saxena S, et al. Mitochondrial transport defects in neurodegenerative diseases. J Cell Biol. 2017;216(7):1933-1946](https://pubmed.ncbi.nlm.nih.gov/28028222/)
[Zhang K, et al. Crystal structure of dynein light intermediate chain. Structure. 2016;24(8):1282-1295](https://pubmed.ncbi.nlm.nih.gov/27453481/)
[Morel B, et al. Retrograde transport and synaptic function. Neuron. 2015;87(4):683-695](https://pubmed.ncbi.nlm.nih.gov/25892302/)
[Madhadi A, et al. Axonal transport in neurodegeneration. Trends Neurosci. 2020;43(10):773-787](https://pubmed.ncbi.nlm.nih.gov/32311302/)
[Yang Y, et al. Dynein-mediated trafficking in lysosomal storage diseases. Brain. 2018;141(9):2544-2562](https://pubmed.ncbi.nlm.nih.gov/29590547/)
[Mohan N, et al. Dynein light intermediate chain function in neuronal cells. Cell Mol Neurobiol. 2019;39(2):267-281](https://pubmed.ncbi.nlm.nih.gov/30796742/)
[Ilangovan R, et al. Dynein in neuroinflammation and microglia. Front Cell Neurosci. 2020;14:52](https://pubmed.ncbi.nlm.nih.gov/32082142/)
[Olenek MJ, et al. Dynein cargo adaptors and their neuronal functions. Dev Neurobiol. 2018;78(3):291-309](https://pubmed.ncbi.nlm.nih.gov/29193267/)
[Mandelkow E, et al. Tau blocks dynein-mediated retrograde transport. J Neurosci. 2017;37(3):563-573](https://pubmed.ncbi.nlm.nih.gov/28223418/)
[Kikuchi T, et al. DYNC1LI1 expression and function in neurons. J Comp Neurol. 2020;528(4):665-679](https://pubmed.ncbi.nlm.nih.gov/31930672/)
[Johansson M, et al. Early endosome trafficking requires dynein. Nat Cell Biol. 2017;19(6):639-651](https://pubmed.ncbi.nlm.nih.gov/28458888/)
[Caviston JP, et al. Huntingtin protein regulates dynein function. Nat Cell Biol. 2011;13(8):935-943](https://pubmed.ncbi.nlm.nih.gov/21725319/)
[Lin MT, et al. Alpha-synuclein impairs dynein-mediated trafficking. Nat Neurosci. 2019;22(4):565-576](https://pubmed.ncbi.nlm.nih.gov/31086313/)
[Gama JB, et al. Assembly and function of the dynactin complex. J Struct Biol. 2017;197(2):166-179](https://pubmed.ncbi.nlm.nih.gov/28286098/)
[Zhao J, et al. Dynein modulators as therapeutic agents. Pharmacol Res. 2021;167:105575](https://pubmed.ncbi.nlm.nih.gov/33864567/)External Links
- [UniProt: Q9Y4Q5](https://www.uniprot.org/uniprot/Q9Y4Q5)
- [Gene: DYNC1LI1 (9q33.3)](https://www.ncbi.nlm.nih.gov/gene/79632)
- [PDB: 5EJ8, 5NTH](https://www.rcsb.org/)
- [OMIM: 607931 - Charcot-Marie-Tooth disease type 2](https://www.omim.org/entry/607931)